Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 17/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 17/20 | 1.00 |
| ▸ | PDE1A | P54750 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18185935 | 0.91 | PDE1B (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185805 | 0.86 | PDE1B (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185675 | 0.85 | PDE1C (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185797 | 0.85 | PDE1C (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185867 | 0.85 | PDE1B (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185776 | 0.85 | PDE1B (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185926 | 0.85 | PDE1A (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185692 | 0.84 | PDE1B (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185694 | 0.84 | PDE1B (1.00) | PDE1CPDE1BPDE1A | |
| SCHEMBL18185892 | 0.84 | PDE1A (1.00) | PDE1CPDE1BPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | claimed |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-09 | — | — | US | claimed |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-02 | — | — | US | claimed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | claimed |
| EP-3532064-B1 | COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | claimed |
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECK A/S (DK) | 2019-09-19 | — | — | US | claimed |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECKA/S (DK) | 2019-09-19 | — | — | US | claimed |
| EP-3532053-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. Lundbeck A/S (DK) | 2019-09-04 | — | — | EP | claimed |
| EP-3288944-B1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2019-06-12 | — | — | EP | claimed |
| WO-2018078042-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECK A/S (DK) | 2018-05-03 | — | — | WO | claimed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | claimed |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-09 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| WO-2016174188-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174188-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE1B, PDE1A | PDE1C 5/4885PDE1B 2/4885PDE1A 3/4885 |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | PDE12, PDE4A, PDE5A | PDE1C 15/4885PDE1B 10/4885PDE1A 7/4885 |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | PDE1C 15/4885PDE1B 10/4885PDE1A 7/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | PDE1C 15/4885PDE1B 10/4885PDE1A 7/4885 |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | PDE1C 15/4885PDE1B 10/4885PDE1A 7/4885 |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | PDE5A, PDE3A, PDE12 | PDE1C 14/4885PDE1B 10/4885PDE1A 7/4885 |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | PDE1A, PDE12, PDE1B | PDE1C 7/4885PDE1B 3/4885PDE1A 1/4885 |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE4A, PDE1A | PDE1C 10/4885PDE1B 4/4885PDE1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.